OK so you thought the title of the other thread was out of date BUT unfortunately there is no way to edit thread titles.

So here is a new title

This one has got the charts at the top again & has a link to the old one.
http://www.moneyam.com/InvestorsRoom/posts.php?tid=5021

Anything that looks too good to be true normally is but as I am a greedy bugger I am hanging on (for fame & fortune, or total bankruptcy).

Possibly due to the imminent ASCO meeting in Florida?

I believe that during one of the webcasts, Prof. Kingsman said that some more
data for Trovax would be presented at ASCO.

Also might explain why there was no accompanying statement following the AGM, as the abstracts for papers presented will be embargoed until the start of the conference.

Possibly....

Thanks mcp2

mcp2 - I believe that OXB have asked for a modified embargo on the information that will be presented at ASCO. There is a facility for this to occur. This request was acceded to last week which "might" suggest that OXB will put out an rns tomorrow (if they consider it worthwhile). However, I am not holding my breath.

Bugger - how did I miss this at 10.30???????

Oxford Biomedica PLC
12 May 2005


FOR IMMEDIATE RELEASE 12 MAY 2005

OXFORD BIOMEDICA TO PRESENT NEW TROVAX(R) DATA
FROM PHASE II TRIALS IN COLORECTAL CANCER AT THE 2005 ASCO
ANNUAL MEETING ON 15 MAY


Oxford, UK: 12 May 2005 - Oxford BioMedica (LSE: OXB), the leading gene therapy
company, today announced that new data from the Phase II trials of TroVax, its
cancer immunotherapy, in colorectal cancer will be presented on 15 May at the
2005 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in
Orlando, Florida, USA, on 13-17 May 2005. Details are as follows:

"An Open Label Phase II Study of MVA Expressing the Tumour Antigen 5T4 Given in
Conjunction with Chemotherapy: Safety and Immunogenicity Before, During and
After Chemotherapy." (Abstract #30642)

Session: Developmental Therapeutics, Immunotherapy
Sunday 15 May, 8:00 am - 12:00 noon, Level 2, Hall C, H10

This abstract may be accessed online at http://www.asco.org/ at the conclusion
of the meeting.

The presentation describes two Phase II trials of TroVax in first line treatment
of metastatic colorectal cancer alongside irinotecan-based (IFL) and
oxaliplatin-based (FOLFOX) chemotherapy. Oxford BioMedica previously reported
encouraging results from the trials in March 2005. The new data include analysis
of immune responses and clinical benefit.

Enrolment in the trials was completed in September 2004 with 36 patients
recruited. The trials are on track to report full safety and immunological data
as well as final tumour response statistics in the second half of 2005. Patient
survival, which can be compared to historical controls, will be reported once
the median survival has been reached in the two trials. This is anticipated in
early 2006.

Commenting on the ASCO presentation of Phase II results for TroVax, Oxford
BioMedica's Chief Scientific Officer, Dr Sue Kingsman, said: "We are very
pleased with the progress of TroVax in clinical trials and look forward to
presenting new data at ASCO

Reduction by about 2.5m in an existing holding:

Oxford Biomedica PLC
12 May 2005


Oxford BioMedica plc (the 'Company')

Notification of Major Interests in Shares

The Company has received notification today from Man Financial Limited that on
11 May 2005 it was the beneficial owner of 27,800,600 Oxford BioMedica plc 1p
ordinary shares. This represents 7.42% of the presently issued share capital of
the Company, which stands at 374,850,009 shares.

12 May 2005

Looks as if they're reducing further or someone else is - two 635k sells gone through this morning.

16/05/05 08:12 Oxford Biomedica announces 'encouraging' TroVax Phase II results AFX

OXB Fairly quiet so far today after recent increases, maybe it will drop again soon.

Or may be, and hopefully, it is a period of consolidation and a lull before the storm.

Yep, down 5.3% so far today.

A little bit more & it may be worth buying some more.

Apple - Do you know I'm tired of reading about your desire for the OXB sp to drop so you can buy, only to sell when it's inched up a penny or two. We all know you do this so do us all a favour and don't labour the fact all the time.

queen1 Do you think this thread has any real affect on the SP. Let him/her practice their keyboard skills.

Well then queen1, if you are tired then have a sleep.

If reading this bores you to sleep then I'm glad that I could help.

Fred1new - no, I don't think the thread has any affect at all it just seems as though the apple record is stuck and needs changing.

apple - I wouldn't have an issue if you weren't always so smug about the whole thing. Still, it must be nice to be right all the time. Bless you.

queen1 I think you had a holding in BRW a while ago and got out with profit. Price dropped back to <=100 but had good results 1/6/05 price going up. Unfortunately did not sell at 140p but expect or see it again within 3-4/12. now about 105 Dyoh

Good memory Fred1new! I have been monitoring BRW and may look again if strength through 130p persists. Best of luck to you with your current holding.

anybody got a reason why the heavy downside today???

Yeh - down 7% and currently with more "recorded" buyers than sellers. Anyone have an educated view?

June is not the month to have an educated view so I'll demonstrate my ignorance. Presumably MMs will squeeze the sp to get rid of weak holders in the light of the recent strong sp performance. Until there is further announcements expect the sp to oscillate quite wildly.